Oral delivery of dextran-modified albumin nanoparticles loaded with shikonin for targeted therapy of colorectal cancer
Source abstract
Abstract
Abstract Background Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality worldwide. Methods In this study, we developed a novel nanomedicine-based therapeutic approach targeting key molecules involved in the progression of CRC. By utilizing bioinformatics tools and computer simulations, we identified SLC2A1 and PKM2 as potential therapeutic targets for CRC. Through molecular docking, we confirmed that shikonin (SHK), a bioactive compound derived from traditional herbal medicine, could effectively bind to SLC2A1 and PKM2, indicating its potential therapeutic effect. The novel SHK-loaded nanoplatform, functionalized with albumin (BSA) and glycoside modification (gBSA/SHK), was designed to enhance stability and targeted delivery to tumor sites. Results In vitro and in vivo experiments showed that SHK-loaded nanoparticles exhibited good tumoricidal effects on CT26 colorectal cancer cells and shifted tumor cell metabolism. Conclusions Overall, our results suggest that SHK-loaded nanodrugs can effectively target key molecular pathways in CRC and provide a promising strategy for colorectal cancer treatment with advantages such as improved drug stability, tumor-specific targeting, and reduced systemic toxicity.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bioactive Compounds and Antitumor Agents · Natural Compound Pharmacology Studies · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669–85.10.1001/jama.2021.0106 ↗
2. Cao F, Jin L, Zhang C, Gao Y, Qian Z, Wen H, et al. Engineering clinically relevant probiotics with switchable “nano-promoter” and “nano-effector” for precision tumor therapy. Adv Mater. 2024;36:2304257.10.1002/adma.202304257 ↗
3. Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20:516–31.10.1038/s41568-020-0273-y ↗
4. Lu Y, Bi T, Zhou S, Guo M. MEX3A promotes angiogenesis in colorectal cancer via glycolysis. Libyan J Med. 2023;18(1):2202446. https://doi.org/10.1080/19932820.2023.2202446.10.1080/19932820.2023.2202446 ↗
5. Apostolova P, Pearce EL. Lactic acid and lactate: revisiting the physiological roles in the tumor microenvironment. Trends Immunol. 2022;43:969–77.10.1016/j.it.2022.10.005 ↗
6. Long L, Xiong W, Lin F, Hou J, Chen G, Peng T, et al. Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery. J Exp Clin Cancer Res. 2023;42:117.10.1186/s13046-023-02688-z ↗
7. Yan C, Li Q, Sun Q, Yang L, Liu X, Zhao Y, et al. Promising nanomedicines of shikonin for cancer therapy. Int J Nanomedicine. 2023;18:1195–218.10.2147/IJN.S401570 ↗
8. Sun Q, Gong T, Liu M, Ren S, Yang H, Zeng S, et al. Shikonin, a naphthalene ingredient: therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches. Phytomedicine. 2022;94:153805. https://doi.org/10.1016/j.phymed.2021.153805.10.1016/j.phymed.2021.153805 ↗
9. Lamichhane S, Lee S. Albumin nanoscience: homing nanotechnology enabling targeted drug delivery and therapy. Arch Pharm Res. 2020;43:118–33.10.1007/s12272-020-01204-7 ↗
10. Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther. 2015;9:3767–77.10.2147/DDDT.S88023 ↗
11. Lin YW, Lin TT, Chen CH, Wang RH, Lin YH, Tseng TY, et al. Enhancing efficacy of albumin-bound paclitaxel for human lung and colorectal cancers through autophagy receptor sequestosome 1 (SQSTM1)/p62-mediated nanodrug delivery and cancer therapy. ACS Nano. 2023;17:19033–51.10.1021/acsnano.3c04739 ↗
12. Canonico F, Pedicino D, Severino A, Vinci R, Flego D, Pisano E, et al. GLUT-1/PKM2 loop dysregulation in patients with non-ST-segment elevation myocardial infarction promotes metainflammation. Cardiovasc Res. 2023;119:2653–62.10.1093/cvr/cvac184 ↗
13. Guo C, He J, Song X, Tan L, Wang M, Jiang P, et al. Pharmacological properties and derivatives of shikonin—a review in recent years. Pharmacol Res. 2019;149:104463. https://doi.org/10.1016/j.phrs.2019.104463.10.1016/j.phrs.2019.104463 ↗
14. Li MY, Mi C, Wang KS, Wang Z, Zuo HX, Piao LX, et al. Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling. Chem Biol Interact. 2017;274:58–67.10.1016/j.cbi.2017.06.029 ↗
15. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, et al. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature. 2011;480:118–22.10.1038/nature10598 ↗
16. Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015;14(1):1–10. https://doi.org/10.1016/j.clcc.2014.11.002.10.1016/j.clcc.2014.11.002 ↗
17. Bak A, Ashford M, Brayden DJ. Local delivery of macromolecules to treat diseases associated with the colon. Adv Drug Deliv Rev. 2018;136–137:2–27. https://doi.org/10.1016/j.addr.2018.10.009.10.1016/j.addr.2018.10.009 ↗
18. Gelibter AJ, Caponnetto S, Urbano F, Emiliani A, Scagnoli S, Sirgiovanni G, et al. Adjuvant chemotherapy in resected colon cancer: when, how and how long? Surg Oncol. 2019;30:100–7.10.1016/j.suronc.2019.06.003 ↗
19. Shen MY, Liu TI, Yu TW, Kv R, Chiang WH, Tsai YC, et al. Hierarchically targetable polysaccharide-coated solid lipid nanoparticles as an oral chemo/thermotherapy delivery system for local treatment of colon cancer. Biomaterials. 2019;197:86–100.10.1016/j.biomaterials.2019.01.019 ↗
20. Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med. 2015;66:83–95.10.1146/annurev-med-051513-102539 ↗
21. Van Cutsem EJ, Oliveira J. Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):ii29-30.10.1093/annonc/mdn077 ↗
22. Ma J, Zhang Y, Tang K, Zhang H, Yin X, Li Y, et al. Reversing drug resistance of soft tumor-repopulating cells by tumor cell-derived chemotherapeutic microparticles. Cell Res. 2016;26:713–27.10.1038/cr.2016.53 ↗
23. Wang H, Tang Y, Fang Y, Zhang M, Wang H, He Z, et al. Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of Shikonin/JQ1. Nano Lett. 2019;19:2935–44.10.1021/acs.nanolett.9b00021 ↗
24. Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 2016;16:2829–37.10.1016/j.celrep.2016.08.032 ↗
25. Andújar I, Ríos JL, Giner RM, Recio MC. Pharmacological properties of shikonin - a review of literature since 2002. Planta Med. 2013;79:1685–97.10.1055/s-0033-1350934 ↗
26. Ma Y, Lai X, Wen Z, Zhou Z, Yang M, Chen Q, et al. Design, synthesis and biological evaluation of novel modified dual-target shikonin derivatives for colorectal cancer treatment. Bioorg Chem. 2023;139:106703. https://doi.org/10.1016/j.bioorg.2023.106703.10.1016/j.bioorg.2023.106703 ↗
27. Kretschmer N, Hufner A, Durchschein C, Popodi K, Rinner B, Lohberger B, et al. Synthesis and pharmacological in vitro investigations of novel shikonin derivatives with a special focus on cyclopropane bearing derivatives. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22052774.10.3390/ijms22052774 ↗
28. He H, Bai LP, Jiang ZH. Synthesis and human telomeric G-quadruplex DNA-binding activity of glucosaminosides of shikonin/alkannin. Bioorg Med Chem Lett. 2012;22:1582–6.10.1016/j.bmcl.2011.12.143 ↗
29. Li B, Zhu M, Ma H, Ma T, Dai Y, Li H, et al. Biosynthesis of novel shikonin glucosides by enzymatic glycosylation. Chem Pharm Bull. 2019;67:1072–5.10.1248/cpb.c19-00284 ↗
30. Shao YY, Yin Y, Lian BP, Leng JF, Xia YZ, Kong LY. Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site. Eur J Med Chem. 2020;190:112105. https://doi.org/10.1016/j.ejmech.2020.112105.10.1016/j.ejmech.2020.112105 ↗
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.10.1016/j.cell.2011.02.013 ↗
32. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33. https://doi.org/10.1126/science.1160809.10.1126/science.1160809 ↗
33. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85–95.10.1038/nrc2981 ↗
34. Cha PH, Hwang JH, Kwak DK, Koh E, Kim KS, Choi KY. APC loss induces Warburg effect via increased PKM2 transcription in colorectal cancer. Br J Cancer. 2021;124:634–44.10.1038/s41416-020-01118-7 ↗
35. Jing Z, Liu Q, He X, Jia Z, Xu Z, Yang B, et al. NCAPD3 enhances Warburg effect through c-myc and E2F1 and promotes the occurrence and progression of colorectal cancer. J Exp Clin Cancer Res. 2022;41:198.10.1186/s13046-022-02412-3 ↗
36. Zhao G, Yuan H, Li Q, Zhang J, Guo Y, Feng T, et al. DDX39B drives colorectal cancer progression by promoting the stability and nuclear translocation of PKM2. Signal Transduct Target Ther. 2022;7:275.10.1038/s41392-022-01096-7 ↗
37. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230–3.10.1038/nature06734 ↗
38. Dayton TL, Jacks T, Vander Heiden MG. PKM2, cancer metabolism, and the road ahead. EMBO Rep. 2016;17:1721–30.10.15252/embr.201643300 ↗
39. Zahra K, Dey T, Ashish, Mishra SP, Pandey U. Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis. Front Oncol. 2020;10:159.10.3389/fonc.2020.00159 ↗
40. Ganapathy-Kanniappan S. Molecular intricacies of aerobic glycolysis in cancer: current insights into the classic metabolic phenotype. Crit Rev Biochem Mol Biol. 2018;53:667–82.10.1080/10409238.2018.1556578 ↗